{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Malignant+Melanoma%2C+Metastatic&page=13", "query": { "condition": "Malignant Melanoma, Metastatic", "page": 13 }, "page_size": 10 }, "pagination": { "page": 13, "page_size": 10, "total_count": 1026, "total_pages": 103, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Malignant+Melanoma%2C+Metastatic&page=14&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Malignant+Melanoma%2C+Metastatic&page=12&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T08:49:29.564Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04423029", "title": "A Study of DF6002 Alone and in Combination With Nivolumab", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "DF6002", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dragonfly Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 170, "start_date": "2020-07-13", "completion_date": "2025-11-26", "has_results": false, "last_update_posted_date": "2026-03-18", "last_synced_at": "2026-10-14T08:49:29.564Z", "location_count": 21, "location_summary": "Orange, California • Denver, Colorado • New Haven, Connecticut + 17 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Miami", "state": "Florida" }, { "city": "Augusta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04423029" }, { "nct_id": "NCT05611229", "title": "Treatment Patterns and Outcomes of Targeted Therapy and Immunotherapy Among BRAF-Positive Melanoma Patients Treated in the Adjuvant Setting and Among BRAF-Positive Metastatic Melanoma Patients With Low Tumor Burden", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Metastatic Melanoma" ], "interventions": [ { "name": "Nivolumab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Dabrafenib+Trametinib", "type": "COMBINATION_PRODUCT" }, { "name": "Ipilimumab+Nivolumab", "type": "COMBINATION_PRODUCT" }, { "name": "Vemurafenib+Cobimetinib", "type": "COMBINATION_PRODUCT" }, { "name": "Encorafenib+Binimetinib", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "DRUG", "COMBINATION_PRODUCT" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1975, "start_date": "2020-06-16", "completion_date": "2021-12-03", "has_results": false, "last_update_posted_date": "2023-04-06", "last_synced_at": "2026-10-14T08:49:29.564Z", "location_count": 1, "location_summary": "East Hanover, New Jersey", "locations": [ { "city": "East Hanover", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05611229" }, { "nct_id": "NCT01350401", "title": "Phase I/II Study to Assess the Safety and Activity of Enhanced TCR Transduced Autologous T Cells in Metastatic Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Autologous genetically modified T cells, NY-ESO-1ᶜ²⁵⁹T", "type": "GENETIC" } ], "intervention_types": [ "GENETIC" ], "sponsor": "Adaptimmune", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2011-06-01", "completion_date": "2018-03-01", "has_results": true, "last_update_posted_date": "2019-01-10", "last_synced_at": "2026-10-14T08:49:29.564Z", "location_count": 2, "location_summary": "New Haven, Connecticut • St Louis, Missouri", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT01350401" }, { "nct_id": "NCT01364051", "title": "Cediranib Maleate and Selumetinib Sulfate in Treating Patients With Solid Malignancies", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Melanoma", "Refractory Malignant Solid Neoplasm", "Stage IV Cutaneous Melanoma AJCC v6 and v7", "Unresectable Malignant Solid Neoplasm" ], "interventions": [ { "name": "Cediranib", "type": "DRUG" }, { "name": "Cediranib Maleate", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Selumetinib", "type": "DRUG" }, { "name": "Selumetinib Sulfate", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2011-05-25", "completion_date": "2027-03-31", "has_results": false, "last_update_posted_date": "2026-09-10", "last_synced_at": "2026-10-14T08:49:29.564Z", "location_count": 2, "location_summary": "Jacksonville, Florida • Rochester, Minnesota", "locations": [ { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01364051" }, { "nct_id": "NCT02029729", "title": "RTA 408 in the Treatment of Advanced Solid Tumors (NSCLC & Melanoma) - DISCOVER", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic or Incurable Non-small Cell Lung Cancer", "Relapsed, Refractory Melanoma" ], "interventions": [ { "name": "omaveloxolone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Biogen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 11, "start_date": "2013-12-31", "completion_date": "2015-10-01", "has_results": false, "last_update_posted_date": "2025-05-29", "last_synced_at": "2026-10-14T08:49:29.564Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02029729" }, { "nct_id": "NCT03068624", "title": "Autologous CD8+ SLC45A2-Specific T Lymphocytes With Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Malignant Neoplasm in the Liver", "Metastatic Uveal Melanoma" ], "interventions": [ { "name": "Aldesleukin", "type": "BIOLOGICAL" }, { "name": "Autologous CD8+ SLC45A2-specific T Lymphocytes", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2017-09-08", "completion_date": "2025-07-31", "has_results": false, "last_update_posted_date": "2024-01-25", "last_synced_at": "2026-10-14T08:49:29.564Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03068624" }, { "nct_id": "NCT00970996", "title": "Cisplatin, Temozolomide, Abraxane, With Interleukin-2 and Interferon for Metastatic Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Temozolomide", "type": "DRUG" }, { "name": "Abraxane", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Interleukin-2", "type": "BIOLOGICAL" }, { "name": "Interferon alpha 2b", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 10, "start_date": "2009-09", "completion_date": "2012-12", "has_results": false, "last_update_posted_date": "2013-01-03", "last_synced_at": "2026-10-14T08:49:29.564Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00970996" }, { "nct_id": "NCT05076760", "title": "MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor", "Advanced Cancer", "Metastatic Cancer", "Non Small Cell Lung Cancer", "Cutaneous Squamous Cell Carcinoma", "Merkel Cell Carcinoma", "Melanoma", "Pancreatic Cancer", "Triple Negative Breast Cancer", "Head and Neck Cancer" ], "interventions": [ { "name": "MEM-288 Intratumoral Injection", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Memgen, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2022-04-21", "completion_date": "2031-12", "has_results": false, "last_update_posted_date": "2026-06-11", "last_synced_at": "2026-10-14T08:49:29.564Z", "location_count": 2, "location_summary": "Tampa, Florida • Durham, North Carolina", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT05076760" }, { "nct_id": "NCT00256282", "title": "Docetaxel and Vinorelbine Plus Sargramostim in Metastatic Malignant Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Melanoma" ], "interventions": [ { "name": "Vinorelbine", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Sargramostim", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "John P. Fruehauf", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 52, "start_date": "2003-04", "completion_date": "2012-08", "has_results": true, "last_update_posted_date": "2018-05-03", "last_synced_at": "2026-10-14T08:49:29.564Z", "location_count": 1, "location_summary": "Orange, California", "locations": [ { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00256282" }, { "nct_id": "NCT05562791", "title": "A Study of 68Gallium PSMA-PET/CT Scans in People With Bladder Cancer or Skin Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Bladder Cancer" ], "interventions": [ { "name": "[68Ga]PSMA", "type": "DRUG" }, { "name": "PET/CT imaging", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DRUG", "DIAGNOSTIC_TEST" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2022-09-28", "completion_date": "2027-09", "has_results": false, "last_update_posted_date": "2026-04-22", "last_synced_at": "2026-10-14T08:49:29.564Z", "location_count": 7, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05562791" } ] }